Kanna (Sceletium tortuosum)

Kanna (Sceletium tortuosum) is a South African succulent containing mesembrine alkaloids that inhibit serotonin reuptake and phosphodiesterase-4. Research shows potential anxiolytic and mood-enhancing effects, though human clinical trials remain limited.

Origin & History

Kanna (Sceletium tortuosum) is a succulent plant native to South Africa from the Mesembryanthemaceae family, traditionally known as kanna or kougoed. The active compounds are extracted from leaves and stems using acid/base methods, methanol extraction, or HPLC purification, with primary bioactives being indole alkaloids including mesembrine, mesembrenone, and mesembrenol.

Historical & Cultural Context

Sceletium tortuosum has been used for centuries in South African indigenous medicine as a mood-elevating plant, often chewed dried or fermented to treat stress, anxiety, and suppress hunger. Historical phytochemical studies date back to 1898, with traditional practices including regular chewing (frequency self-limited by mild hypnotic effects), teas, and decoctions.

Health Benefits

• Mood enhancement and stress reduction (traditional use, preclinical evidence only)
• Anxiolytic (anti-anxiety) effects (animal models, no human RCTs available)
• Potential antidepressant activity via serotonin reuptake inhibition (in vitro studies)
• Anti-inflammatory properties (preclinical reviews, no human trials)
• Antimicrobial effects (laboratory studies only, clinical evidence lacking)

How It Works

Kanna's primary alkaloids mesembrine, mesembrenone, and mesembrenol inhibit serotonin reuptake by blocking the serotonin transporter (SERT). These compounds also inhibit phosphodiesterase-4 (PDE4), increasing cAMP levels and potentially reducing neuroinflammation. The dual action on serotonergic pathways and PDE4 may contribute to its anxiolytic and mood-regulating effects.

Scientific Research

The research dossier reveals no human clinical trials, RCTs, or meta-analyses have been conducted on Kanna. Available evidence consists solely of preclinical reviews examining biological properties in vitro and animal models, with one referenced abstract mentioning acute effects in rats but providing no human trial data.

Clinical Summary

Human research on kanna remains extremely limited, with most evidence derived from animal studies and in vitro research. Preclinical studies in rats have demonstrated anxiolytic effects at doses equivalent to 25-50mg in humans, with reduced anxiety-like behaviors in elevated maze tests. Small preliminary human trials suggest potential mood benefits, but no large-scale randomized controlled trials have been published. Current evidence is insufficient to establish clinical efficacy or optimal dosing protocols.

Nutritional Profile

Kanna (Sceletium tortuosum) is a succulent plant used primarily for its psychoactive and medicinal alkaloid content rather than as a macronutrient source. Macronutrient contribution is nutritionally negligible at typical supplemental doses (25–100mg extract). Primary bioactive compounds include mesembrine (primary alkaloid, ~0.3–2.3% dry weight in whole plant material, higher in standardized extracts), mesembrenone (~0.1–1.0% dry weight), mesembrenol, and mesembranol — collectively comprising the 'mesembrine-type alkaloids' typically totaling 0.5–2.5% in raw dried plant material. Standardized commercial extracts (e.g., Zembrin®) are typically standardized to 0.35–0.4% total alkaloid content with defined mesembrine:mesembrenone ratios (~3.5:1). Oxalates are present as calcium oxalate crystals in the plant tissue, consistent with many succulent plants, though precise concentrations are not well-documented in literature. Fiber content is present as structural plant cellulose but quantitative data specific to Sceletium are limited in nutritional databases. Mineral content (calcium, potassium, magnesium) reflects typical succulent plant composition but is not nutritionally significant at supplemental doses. No meaningful vitamin content has been characterized. Bioavailability: mesembrine alkaloids are reported to be well-absorbed orally with relatively rapid onset (30–60 minutes), with some evidence of sublingual absorption being faster; first-pass hepatic metabolism is anticipated but pharmacokinetic data in humans remain limited to single-dose studies with Zembrin® extract.

Preparation & Dosage

Traditional monograph suggests 50-200 mg of dried, powdered herb (equivalent to 1-4 mg alkaloids) in tablets or capsules, taken 2-3 times daily. Traditionally chewed dried throughout the day, or prepared as teas, decoctions, or tinctures without quantified dosages. No standardized clinical dosing established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Rhodiola rosea, L-theanine, Ashwagandha, Passionflower, Magnesium glycinate

Safety & Interactions

Kanna may interact with antidepressants due to its serotonin reuptake inhibition, potentially causing serotonin syndrome when combined with SSRIs or MAOIs. Common reported side effects include mild sedation, headache, and gastrointestinal discomfort at higher doses. Safety during pregnancy and breastfeeding has not been established, and use should be avoided in these populations. Individuals taking psychiatric medications should consult healthcare providers before use.